Pulsenmore to Begin Trading on Nasdaq
Pulsenmore Ltd. filed a report describing that its shares will begin trading on the Nasdaq Capital Market, while continuing to trade on the Tel Aviv Stock Exchange.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Pulsenmore Ltd. filed a report describing that its shares will begin trading on the Nasdaq Capital Market, while continuing to trade on the Tel Aviv Stock Exchange. The company develops home-use ultrasound and telehealth technology that lets physicians supervise prenatal monitoring outside traditional clinics, using proprietary hardware, secure cloud image transmission, and clinical review workflows.
Pulsenmore highlights that it has FDA authorization for its home-use prenatal ultrasound system and describes this as the first and only FDA-authorized home-use prenatal ultrasound system. Management views the Nasdaq listing as a transformative step that may increase visibility and liquidity and help attract a broader, global investor base aligned with its maternal-health focused growth strategy.
Insights
Pulsenmore gains Nasdaq listing alongside FDA-cleared home prenatal ultrasound platform.
Pulsenmore is moving its ordinary shares onto the Nasdaq Capital Market while remaining listed on the Tel Aviv Stock Exchange. The company develops home-use prenatal ultrasound devices and telehealth workflows, combining proprietary hardware, cloud image transfer, and clinician review to support remote maternal care.
The text notes that Pulsenmore has FDA authorization for its home-use prenatal ultrasound system and characterizes it as the first and only FDA-authorized home-use prenatal ultrasound system. Management frames the Nasdaq listing as a transformative step expected to enhance visibility and liquidity and to support engagement with leading U.S. medical centers and hospitals.
The impact for investors depends on how effectively the company uses this higher-profile listing to support commercialization and partnerships in the United States. Future SEC reports and company communications may provide more detail on revenue generation, capital needs, and U.S. market traction.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Pulsenmore (PLSM) announce in its latest 6-K filing?
Pulsenmore announced that its ordinary shares will begin trading on the Nasdaq Capital Market while also continuing to trade on the Tel Aviv Stock Exchange.
What does Pulsenmore (PLSM) do in the healthcare sector?
Pulsenmore is a digital health company developing home-use ultrasound and telehealth technology that enables physician-supervised prenatal monitoring outside traditional clinical settings.
What regulatory status does Pulsenmores prenatal ultrasound device have?
Pulsenmore states that it has FDA authorization for its home-use prenatal ultrasound system and describes it as the first and only FDA-authorized home-use prenatal ultrasound system.
Where does Pulsenmore (PLSM) operate and with whom does it collaborate?
Pulsenmore operates in select international markets in collaboration with healthcare systems and providers, focusing on maternal health and remote prenatal care.
Where can investors follow updates from Pulsenmore (PLSM)?
Investors are directed to Pulsenmores investor relations page, its LinkedIn account, as well as its SEC filings, press releases, public conference calls, and webcasts for material information.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of January 2026
001-43033
(Commission File Number)
PULSENMORE LTD.
(Exact name of Registrant as specified in its charter)
8 Omarim St.
Omer 8496500, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On January 21, 2026, Pulsenmore Ltd. (the “Company”) issued a press release entitled “Pulsenmore To Commence Trading on Nasdaq as It Expands FDA-authorized Home Prenatal Ultrasound Devices in the U.S.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Investors and others should note that the Company may announce material information about its finances, products, and other matters to its investors using the investor relations page of its website (pulsenmore.com/investor_relations/) and its Linkedin account (linkedin.com/company/pulsenmore/) in addition to SEC filings, press releases, public conference calls and webcasts. The Company uses these channels to communicate with the Company’s shareholders and the public about the Company and other issues. It is possible that the information the Company posts on these channels could be deemed to be material information. Therefore, the Company encourages investors, the media, and others interested in the Company to review the information it posts on the Company’s website and LinkedIn account in addition to following its press releases, SEC filings, public conference calls, and webcasts.
EXHIBIT INDEX
Exhibit No. |
Description | |
| 99.1 | Press Release, dated January 21, 2026. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Pulsenmore Ltd. | ||
| Date: January 21, 2026 | By: | /s/ Dr. Elazar Sonnenschein |
| Dr. Elazar Sonnenschein | ||
| Chief Executive Officer | ||
Exhibit 99.1
Pulsenmore To Commence Trading on Nasdaq as It Expands FDA-authorized Home Prenatal Ultrasound Devices in the U.S.
Ramat Gan, Israel, Jan. 21, 2026 /PRNewswire/ — Pulsenmore Ltd. (NASDAQ, TASE: PLSM), a pioneer in home ultrasound technology, today announced that its shares will begin trading on Nasdaq at the U.S. market open today. The Company’s shares will trade under the ticker symbol PLSM on the Nasdaq Capital Market as well as the Tel Aviv Stock Exchange (TASE).
Pulsenmore is a digital health company developing home-use ultrasound and telehealth technology that enables physician-supervised prenatal monitoring outside traditional clinical settings. Its platform combines proprietary ultrasound hardware, secure cloud-based image transmission, and clinical review workflows to improve access, continuity of care, and patient experience.
The Company operates in select international markets in collaboration with healthcare systems and providers. Pulsenmore has received FDA authorization for its home-use prenatal ultrasound system, establishing a regulatory foundation for potential future commercialization in the United States.
“Pulsenmore offers the first and only FDA-authorized home-use prenatal ultrasound system,” said Dr. Elazar Sonnenschein, CEO and founder of Pulsenmore. “As we accelerate our expansion across the U.S. healthcare system and deepen our engagement with leading medical centers and hospitals nationwide, our Nasdaq listing marks a transformative step in the Company’s evolution. We expect this milestone will enhance long-term shareholder value by increasing visibility and liquidity, while providing a powerful platform to attract a broader, global investor base aligned with our growth strategy and mission.”
About Pulsenmore
Pulsenmore Ltd. is dedicated to revolutionizing maternal health through the development of home-use ultrasound technology that connect mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes prenatal care patient-centric, expanding access and improving continuity of care. For more information, visit www.pulsenmore.com
This press release contains forward-looking statements. In particular, statements using words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “contemplate,” “do not believe,” “aim,” “goal,” “due,” “predict,” “plan,” “project,” “continue,” “potential,” “positioned,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to the expected time for Pulsenmore’s ordinary shares to begin trading on the Nasdaq and Pulsenmore’s expectation that the listing of its ordinary shares on the Nasdaq Stock Exchange will enhance long-term shareholder value. Forward-looking statements reflect Pulsenmore’s current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033), filed with the SEC on December 29, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.
Investor Contact:
Miri Segal-Scharia
MS-IR LLC
msegal@ms-ir.com